13F Holdings
中文EN

IRWD IRONWOOD PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1446847 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY18.1%
TTM net income YoY424.1%
TTM EPS YoY400.0%
Revenue 3-yr CAGR-2.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin62.9%
Net margin37.4%
FCF margin—
EBITDA margin63.2%

Returns

ROE—
ROA43.6%
ROIC (approx.)—
Asset turnover1.17x

Leverage & solvency

Liabilities / assets133.4%
Debt / equity—
Current ratio6.51x
Interest coverage8.28x

Cash quality & payout

Operating cash flow / net income1.37x
Accruals ratio-16.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$296.15M$351.41M$442.74M$410.60M$413.75M
R&D expense$95.14M$111.42M$116.08M$44.27M$70.41M
SG&A expense$82.26M$144.27M$158.31M$115.99M$111.13M
Operating income$98.50M$93.12M-$945.43M$250.34M$232.26M
Interest expense$32.75M$33.03M$21.63M$7.60M$31.15M
Pretax income$70.03M$65.20M-$948.07M$252.42M$200.66M
Income tax$46.01M$64.32M$83.49M$77.36M-$327.79M
Net income$24.02M$880,000-$1.00B$175.06M$528.45M
EBITDA$99.60M$94.32M-$944.23M$251.74M$233.76M
EPS (basic)0.150.01-6.451.133.26
EPS (diluted)0.150.01-6.450.963.21
Weighted avg. shares (diluted)162.98M160.08M155.44M186.31M164.42M
Balance sheet
Cash & equivalents$215.46M$88.56M$92.15M$656.20M$621.86M
Receivables$46.74M$81.89M$129.12M$115.46M$114.04M
Current assets$274.18M$182.37M$233.29M$780.63M$745.23M
PP&E, net$3.41M$4.50M$5.58M$6.29M$7.58M
Intangibles$2.04M$2.86M$3.68M——
Total assets$396.90M$350.91M$471.07M$1.10B$1.13B
Current liabilities$242.22M$38.85M$276.10M$25.52M$161.70M
Long-term debt—$198.99M$397.87M$396.25M$454.19M
Total debt—$198.99M$397.87M$396.25M$454.19M
Total liabilities$658.74M$652.24M$817.37M$448.14M$521.02M
Shareholders' equity-$261.83M-$301.33M-$346.30M$652.38M$605.91M
Net debt—$110.43M$305.71M-$259.95M-$167.67M
Shares outstanding163.06M160.21M156.35M154.03M162.04M
Cash flow statement
Operating cash flow$127.04M$103.55M$183.43M$273.76M$261.89M
Capital expenditure$34,000$142,000$273,000$136,000$265,000
Free cash flow$127.01M$103.41M$183.15M$273.63M$261.63M
Investing cash flow-$34,000-$142,000-$1.03B-$136,000-$265,000
Financing cash flow$216,000-$106.97M$277.16M-$237.55M-$4.55M
Depreciation & amortization$1.10M$1.20M$1.20M$1.40M$1.50M
Stock-based compensation$17.25M$29.85M$32.01M$27.05M$22.28M
Share buybacks———$126.39M$24.13M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.